
CDT
Healthcare · Biotechnology · $407,552 market cap
$0.4004-0.04 (-9.7%)Nov 13, 4:20 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | Time not confirmed | — | — | — |
| Aug 12, 2026 | Time not confirmed | — | -8.71 | — |
| Jun 25, 2026 | Time not confirmed | — | -99.99 | — |
| Nov 12, 2025 | After the close | — | -13.16 | — |
| Aug 14, 2025 | After the close | — | -5.46 | — |
| May 15, 2025 | Time not confirmed | — | -1.32 | — |
| Mar 28, 2025 | Time not confirmed | — | -2.15 | — |
| Mar 28, 2023 | Time not confirmed | — | 0.03 | — |
| Nov 7, 2022 | Time not confirmed | — | 0.01 | — |
| Aug 11, 2022 | Time not confirmed | — | -0.01 | — |
| May 18, 2022 | Time not confirmed | — | -0.02 | — |
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2…